Siponimod: Approved indication: multiple sclerosis.
- Published in:
- Australian Prescriber, 2021, v. 44, n. 2, p. 69, doi. 10.18773/austprescr.2021.014
- Publication type:
- Article
Works matching IS 03128008 AND DT 2021 AND VI 44 AND IP 2
Results: 14
1
2
Selexipag: Approved indication: pulmonary arterial hypertension.
- Published in:
- Australian Prescriber, 2021, v. 44, n. 2, p. 67, doi. 10.18773/austprescr.2021.007
- Publication type:
- Article
3
Defibrotide: Approved indication: hepatic veno-occlusive disease.
- Published in:
- Australian Prescriber, 2021, v. 44, n. 2, p. 64, doi. 10.18773/austprescr.2021.010
- Publication type:
- Article
4
Ozanimod: Approved indication: multiple sclerosis.
- Published in:
- Australian Prescriber, 2021, v. 44, n. 2, p. 65, doi. 10.18773/austprescr.2021.013
- Publication type:
- Article
5
Cinnarizine/dimenhydrinate: Approved indication: vertigo.
- Published in:
- Australian Prescriber, 2021, v. 44, n. 2, p. 62, doi. 10.18773/austprescr.2021.009
- Publication type:
- Article
6
ChAdOx1-S vaccine: Approved indication: prevention of COVID-19.
- Published in:
- Australian Prescriber, 2021, v. 44, n. 2, p. 59, doi. 10.18773/austprescr.2021.012
- Publication type:
- Article
7
New drugs: BNT162b2 COVID-19 vaccine.
- Published in:
- Australian Prescriber, 2021, v. 44, n. 2, p. 57, doi. 10.18773/austprescr.2021.008
- Publication type:
- Article
8
Discontinuation of antiepileptic drugs in adults with epilepsy.
- Published in:
- Australian Prescriber, 2021, v. 44, n. 2, p. 53, doi. 10.18773/austprescr.2021.005
- By:
- Publication type:
- Article
9
Balancing the benefits and harms of oral anticoagulation in non-valvular atrial fibrillation.
- Published in:
- Australian Prescriber, 2021, v. 44, n. 2, p. 49, doi. 10.18773/austprescr.2021.002
- By:
- Publication type:
- Article
10
Rational prescribing in community palliative care.
- Published in:
- Australian Prescriber, 2021, v. 44, n. 2, p. 45, doi. 10.18773/austprescr.2021.001
- By:
- Publication type:
- Article
11
Opioids and antidepressants: which combinations to avoid.
- Published in:
- Australian Prescriber, 2021, v. 44, n. 2, p. 41, doi. 10.18773/austprescr.2021.004
- By:
- Publication type:
- Article
12
Letters to the Editor.
- Published in:
- Australian Prescriber, 2021, v. 44, n. 2, p. 40, doi. 10.18773/austprescr.2021.011
- By:
- Publication type:
- Article
13
Naloxone for opioid toxicity and overdose in the community.
- Published in:
- Australian Prescriber, 2021, v. 44, n. 2, p. 38, doi. 10.18773/austprescr.2021.006
- By:
- Publication type:
- Article
14
Elimination of hepatitis C in Australia by 2030: a decade and counting.
- Published in:
- Australian Prescriber, 2021, v. 44, n. 2, p. 36, doi. 10.18773/austprescr.2021.003
- By:
- Publication type:
- Article